Competitor to Amgen’s Epogen also moves closer to market
Company still in race to develop CGRP inhibitor for migraine.
Drug will also be available to children via Cancer Drugs Fund.
Repatha cuts cardio events, but not mortality.
Decision paves way for cheaper competitor in autumn 2018.
Analysis questions industry’s rationale for high US prices.
Biosimilars firm facing court battle.
Viral Safety conference